Abionyx Pharma SA
web2ABIONYX Pharma is a French biotechnology company developing apoA-I-based therapies and biologic...
About
ABIONYX Pharma is a French biotechnology company developing apoA-I-based therapies and biologic candidates for severe inflammatory, renal, and ophthalmological conditions with limited treatment options. Its principal asset, CER-001, is an engineered high-density lipoprotein-like particle containing recombinant apolipoprotein A-I and phospholipids, designed to support reverse lipid transport and removal of excess cholesterol. The company is developing CER-001 for severe inflammation and sepsis and is structuring its bioproduction chain through manufacturing partnerships. Its research also addresses renal and ophthalmological diseases, while its drug candidates remain subject to development and regulatory requirements.
Explore this sector
Exchange listings
Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.
Abionyx Pharma SA profile.
Expert coverage
No published expert evaluations are available for this project yet.
Orbitrum Academy